PERJETA works with Herceptin® (trastuzumab) and docetaxel to fight HER2+ advanced breast cancer

PERJETA is part of a first-line treatment regimen for HER2+ metastatic breast cancer, along with Herceptin and docetaxel. If your doctor has prescribed PERJETA-based treatment for your HER2+ metastatic breast cancer, here is what you can expect.

  • PERJETA is given every 3 weeks, on the same day as Herceptin and docetaxel, during the same visit
  • PERJETA is given as an intravenous infusion through a port, which means that medicine is given directly and slowly into the bloodstream through a vein

PERJETA-based treatment course typically given every 3 weeks

PERJETA Metastatic Dosing Phases

How long a treatment course may take

  • When you are getting treatment, PERJETA, Herceptin, and docetaxel will be given one at a time
  • Infusion time may vary from person to person depending on tolerability
  • After each medicine is given, your doctor or nurse may wait 30–60 minutes to check for any infusion or allergic reactions
  • They may adjust, delay, or stop treatment if a reaction occurs

During your first treatment
The medicines are given more slowly during your first visit. Your first dose of PERJETA will be given as an infusion over 60 minutes. Herceptin will be given over 90 minutes, and docetaxel over 60 minutes.

The role of docetaxel in your treatment plan

Docetaxel, a type of traditional chemotherapy, is an essential part of your treatment with PERJETA and Herceptin. When you begin treatment, your doctor will start all 3 medicines, and may adjust the medicines in your treatment plan over time. Docetaxel is given for a minimum of 6 cycles.

PERJETA and Herceptin can be continued after docetaxel is stopped

PERJETA Metastatic Continued

If your doctor stops docetaxel (eg, due to side effects), you can continue receiving PERJETA and Herceptin. You can stay on PERJETA and Herceptin until your disease is no longer controlled or your side effects require you to stop treatment.

PERJETA for HER2+ metastatic breast cancer

See the potential benefits and risks associated with PERJETA-based treatment for HER2+ metastatic breast cancer.

Talking with your healthcare team

If your HER2+ breast cancer has spread, here are questions you may want to ask your doctor.